BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Tercica, Inc. 

2000 Sierra Point Parkway
Suite 400
Brisbane  California  94005  U.S.A.
Phone: 650-624-4900 Fax: 650-624-4940


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Overview

Tercica, Inc., based in Brisbane, California, is a biopharmaceutical company committed to improving endocrine health. We are helping patients by partnering with the endocrine community to develop and commercialize new therapeutics for short stature, our initial market opportunity, and associated metabolic disorders.

Our flagship product is Increlex™ (mecasermin [rDNA origin] injection), or recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Tercica licensed rights to develop, manufacture, and commercialize Increlex from Genentech, Inc. We are currently conducting a broad-scale Phase IIIb clinical study to evaluate the safety and efficacy of Increlex in children with Primary IGFD.

Beyond Increlex, Tercica intends to build a franchise of endocrinology products through our own internal development efforts and through strategic in-licensing.

History

Tercica was born out of technology and intellectual property from Genentech for recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Founded by noted scientists and clinicians in endocrinology and the field of growth hormone (GH) research, the company began operations in the United States in May, 2002 after licensing from Genentech exclusive rights to develop, commercialize, and manufacture rhIGF-1. Tercica also licensed Genentech rights to the rhIGF-1/IGFBP-3 binding protein complex, as well as to manufacturing processes, formulations, pre-clinical studies and clinical
studies associated with the rhIGF-1 program at Genentech.

The vision of Tercica's founders was to turn the promise of rhIGF-1 as a key mediator of growth and metabolism into a therapeutic reality for several diseases in need of new treatments. Leveraging an intensive multi-national research effort spanning nearly forty years and more than 20,000 publications which further establish IGF-1's central role in the endocrine system, Tercica was founded to bring rhIGF-1 back to its roots in growth biology and metabolism.

Tercica was founded by Professor Ross G. Clark of the University of Auckland; Professor Bengt-Åke Bengtsson, Professor of Endocrinology at Sahlgrenska University in Göteborg, Sweden; Professor Iain C.A.F. Robinson, head of Molecular Neuroendocrinology at the National Institute for Medical Research, Mill Hill, England, and Professor Olle G. P. Isaksson, head of the Department of Internal Medicine at Sahlgrenska University Hospital in Göteborg, Sweden, and by Mr. Howard Moore, our first executive. Professor Clark currently serves as our Chief Technical Officer. Professor Clark and Professor Isaksson serve as members of our Board of Directors.


 Key Statistics


Email:
Ownership: Public

Web Site: Tercica, Inc.
Employees: 112
Investor Relations: Fredrik Wiklund, Sr. Director, Corporate Development and Investor Relations

Symbol: TRCA
 









 Company News
Tercica, Inc. (TRCA) Announces Results from Increlex(R) Phase IIIb Study Demonstrating Dose-Dependent Height Velocity Increase in Primary IGFD Short Stature Population and Other Increlex(R) Studies at the 13th International Congress of Endocrinology Meeting 11/12/2008 11:46:38 AM
Ipsen Completes the Acquisition of Tercica, Inc. (TRCA) in North America, the Third of Its Three Steps to Globalize Its Fast Growing Specialist Care Business 10/17/2008 10:42:08 AM
Tercica, Inc. (TRCA) Reports Second Quarter 2008 Financial Results 7/31/2008 10:34:50 AM
Ipsen Continues the Acquisition Process of Tercica, Inc. (TRCA) so as to Establish Its Global Presence in Endocrinology 7/23/2008 10:50:47 AM
Tercica, Inc. (TRCA) Announces Results from Increlex® IGFD Patient Registry and Other Increlex® Studies at the 90th Meeting of the Endocrine Society 6/16/2008 1:11:51 PM
Ipsen In 3 Deals Worth $450M; Company to Build A Fully-Fledged Commercial Presence In North America -- $404M Tercica, Inc. (TRCA) Merger Deal; Vernalis PLC (VNLS) To Sell Apokyn And U.S. Commercial Operations for $17.5M; Octagon Corp. to be Acquired 6/5/2008 6:29:08 AM
Tercica, Inc. (TRCA) to Present at FBR Capital Markets 12th Annual Spring Investor Conference 5/21/2008 12:35:25 PM
Tercica, Inc. (TRCA) Reports First Quarter 2008 Financial Results 5/13/2008 10:33:23 AM
Tercica, Inc. (TRCA) to Hold 2008 First Quarter Financial Results Conference Call May 12 5/1/2008 9:47:25 AM
Tercica, Inc. (TRCA) to Present at March Investment Conferences 3/11/2008 9:22:12 AM
12345678910...